Skip to main content
. 2024 Apr 11;19(8):2241–2248. doi: 10.1007/s11739-024-03592-w

Table 1.

Characteristics of the study cohort and comparison by administration of routine treatment at the emergency departmenta

Variable Not given n = 88 (%) Routine treatment n = 256 (%) Total n = 344 (%) p
Age, years, median (IQR) 69 (62–79) 71 (63–78) 71 (63–78) 0.98
Female sex 30 (34) 99 (39) 129 (38) 0.44
Charlson score, median (IQR) 5 (3–4) 5 (4–7) 5 (3–7) 0.21
Obese (BMI > 30) 37 (42) 77 (30) 114 (33) 0.04
Heart failure 14 (16) 61 (24) 75 (22) 0.12
Atrial fibrillation 8 (9) 26 (10) 34 (10) 0.77
COPD coded diagnosis 72 (82) 218 (85) 290 (84) 0.46
Prior COPD exacerbation 47 (53) 196 (77) 243 (71)  < 0.01
Emergency department characteristics
 Ambulance transfer 28 (32) 112 (44) 140 (41) 0.05
 Increased dyspnea 75 (85) 238 (93) 313 (91) 0.03
 Increased cough 40 (45) 155 (61) 195 (57) 0.01
 Increased mucus 21 (24) 100 (39) 121 (35) 0.01
 Fever (> 38 °C) 17 (19) 23 (9) 36 (11) 0.01
 O2 saturation < 91% 29 (33) 161 (63) 190 (55)  < 0.01
 Shift
  Day (07:00–15:00) 43 (49) 125 (51) 168 (51) 0.87
  Evening (15:00–23:00) 28 (32) 81 (33) 109 (33)
  Night (23:00–07:00) 16 (18) 39 (16) 55 (17)
 CXR consolidation 11 (13) 21 (8) 32 (9) 0.23
In-hospital variables
 SABD during hospitalization 72 (81) 250 (98) 322 (94)  < 0.01
 Steroids during hospitalization 69 (78) 238 (93) 307 (89)  < 0.01
 Hospital length of stay, median (IQR) 4 (3–6) 4 (3–7) 4 (3–6) 0.28
 In-hospital adverse outcomeb 5 (6) 22 (9) 27 (8) 0.38

Bold values indicate p-value < 0.05

COPD chronic obstructive pulmonary disease, CXR chest X-ray, O2 oxygen, SABD short-acting bronchodilators

aRoutine treatment given at the emergency department, including inhalations of short-acting bronchodilators and/or systemic steroids

bAdverse events include in-hospital mortality, intubation, or transfer to the intensive care unit